BridgeMD
New treatment option for Zhejiang University
Official title The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction
ClinicalTrials.gov ID: NCT07381803
What this study is testing
What is Fexofenadine 60 Mg Oral Tablet?
Fexofenadine 60 Mg Oral Tablet is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for zhejiang university.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this study is o evaluate the prognostic effect of fexofenadine hydrochloride in patients with myocardial infarction
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years old.
- Able to verbally confirm understanding of the trial risks, benefits, and treatment options of fexofenadine hydrochloride therapy. He/she or his/her...
- Acute ST-segment elevation myocardial infarction (STEMI) occurring within 7 days, with diagnostic criteria including: i) Typical clinical symptoms...
- Echocardiography indicating segmental wall motion abnormalities.
You likely can't join if
- Need for long-term use of fexofenadine hydrochloride or other H1 receptor inhibitors.
- Previous coronary artery bypass grafting (CABG) surgery.
- History of severe renal failure with estimated glomerular filtration rate (eGFR) \< 30 ml/min.
- History of severe liver dysfunction.
- History of concurrent severe infection, hepatobiliary obstruction, or malignant tumor.
- Expected life expectancy of less than 2 years due to non-cardiac diseases.
See the full eligibility criteria
- Age ≥ 18 years old.
- Able to verbally confirm understanding of the trial risks, benefits, and treatment options of fexofenadine hydrochloride therapy. He/she or his/her legal representative must provide written informed consent prior to...
- Acute ST-segment elevation myocardial infarction (STEMI) occurring within 7 days, with diagnostic criteria including: i) Typical clinical symptoms: such as severe crushing pain in the retrosternal or precordial area...
- Echocardiography indicating segmental wall motion abnormalities.
- Need for long-term use of fexofenadine hydrochloride or other H1 receptor inhibitors.
- Previous coronary artery bypass grafting (CABG) surgery.
- History of severe renal failure with estimated glomerular filtration rate (eGFR) \< 30 ml/min.
- History of severe liver dysfunction.
- History of concurrent severe infection, hepatobiliary obstruction, or malignant tumor.
- Expected life expectancy of less than 2 years due to non-cardiac diseases.
- Currently receiving immunosuppressive therapy.
- Pregnant, potentially pregnant, or lactating women.
- Contraindication to the study drug or examinations.
- Failure to provide written informed consent.
- Presence of mechanical complications (ventricular septal defect, papillary muscle dysfunction, acute mitral regurgitation), refractory cardiogenic shock unresponsive to vasopressors, acute left heart failure or...
The study team makes the final eligibility decision.
Where it's taking place
- Hangzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hangzhou, Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.